Annual Report 2009 - Daiichi Sankyo
Annual Report 2009 - Daiichi Sankyo
Annual Report 2009 - Daiichi Sankyo
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
(a) 3) Date of acquisition<br />
November 7, 2008<br />
(a) 4) Legal form of acquisition<br />
Share purchase by cash<br />
(a) 5) Name of the company after acquisition<br />
Ranbaxy Laboratories Ltd.<br />
(a) 6) Percentage of voting rights acquired<br />
63.92%<br />
(b) Period of results of acquired company included in the consolidated financial statements<br />
(b) From October 1, 2008 to December 31, 2008<br />
(c) Acquisition cost of acquired company and related breakdown<br />
(c) Acquisition considerations:<br />
Thousands of<br />
Millions of yen U.S. dollars<br />
Share purchases by an open offer ¥169,407 $1,728,643<br />
Share purchases from founding family 230,971 2,356,847<br />
Capital increase subscribed by third party 85,002 867,367<br />
Direct acquisition-related costs 2,974 30,347<br />
Total acquisition cost ¥488,354 $4,983,204<br />
(d) Description of goodwill<br />
(d) 1) Amount of goodwill<br />
¥408,675 million ($4,170,153 thousand)<br />
(d) 2) Reason for recognizing goodwill<br />
Goodwill was recognized as the excess of the acquisition cost over the net of acquired assets and assumed liabilities at<br />
fair value.<br />
(d) 3) Goodwill amortization method and period<br />
Amortized in equal amounts over 20 years<br />
The Company amortized the goodwill (one-time amortization) of Ranbaxy of ¥351,310 million ($3,584,796 thousand) for<br />
the fiscal year ended March 31, <strong>2009</strong>.<br />
(e) Amounts and breakdown of main components of assets acquired and liabilities assumed as of the date of acquisition<br />
Thousands of<br />
Millions of yen U.S. dollars<br />
Current assets ¥241,767 $2,467,010<br />
Non-current assets 151,863 1,549,623<br />
Goodwill, net 408,675 4,170,153<br />
Current liabilities (169,103) (1,725,541)<br />
Long-term liabilities (98,882) (1,009,000)<br />
Subscription rights to shares (6,387) (65,173)<br />
Minority interests (46,489) (474,378)<br />
In-process research and development 6,910 70,510<br />
Total ¥488,354 $4,983,204<br />
(f) Amounts of acquisition cost allocated to research and development expenses charged to earnings<br />
In-process research and development expenses: ¥6,910 million ($70,510 thousand)<br />
(g) Amounts of acquisition cost allocated to intangible assets other than goodwill and amortization period<br />
Breakdown by major type Millions of yen Thousands of U.S. dollars Amortization period<br />
Trademarks related ¥40,984 $418,204 10 years<br />
Leasehold right 5,918 60,388 —<br />
<strong>Daiichi</strong> <strong>Sankyo</strong> Co., Ltd. <strong>Annual</strong> <strong>Report</strong> <strong>2009</strong> 65